Lake Street analyst Brooks O’Neil raised the firm’s price target on Harrow Health (HROW) to $24 from $17 and keeps a Buy rating on the shares after Harrow completed the acquisition of the exclusive U.S. commercial rights to five branded ophthalmic products from Novartis (NVS) and affirmed 2023 guidance. Given the new rights along with fortisite and atropine, the "table is set for big things" from Harrow in 2023, Lake Street tells investors.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on HROW: